Literatur

1. Management des Mammakarzinoms; S. 420; Kreienberg R.; Springer Verlag 2006
2. Bildgebende Diagnostik und Therapie der Weichteiltumoren; S. 161; Breitenseher, M.; Thieme Verlag 2008
3. Knauf WU, Lissichkov, Aldaoud A.
   Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
   J Clin Oncol. 2009. 27:4378-4384
4. Kompendium Internistische Onkologie; S. 2714; Schmoll, H.; Springer Verlag 2005
5. Onkologische Therapie; Bruhn, H.; S. 98-100; Schattauer Verlag 2003
6. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M.
   American Society of Clinical Oncology Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
   McWilliams and Alberts. 2006. 25:1142
7. Robert N, Leyland-Jones B, Asmar L, Belt R.
   Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer
   J Clin Oncol. 2006. 24:2786-2792
8. Conroy T, Paillot B, François E, Bugat R.
   Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer - A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study
   J Clin Oncol. 2005. 23:1228-1236
9. von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N, Kleeberg U, Tsekov C, Fritze D, Thomssen C, Stuart N, Vermorken JB, Loibl S, Merkle Kh, Kaufmann M.
   Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC
   Anticancer Drugs. 2005. 16:871-877
10. Sekeres MA, Elson P, Kalaycio ME.
    Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.
    Blood. 2009. 113:28-36
11. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE.
    Weekly paclitaxel in the adjuvant treatment of breast cancer
    N Engl J Med. 2008. 358:1663-1671
12. Bonneterre J, Roché H, Kerbrat P, Brémond A, Fumoleau P, Namer M, Goudier MJ, Schraub S, Fargeot P, Chapelle-Marcillac I.
     Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial
    J Clin Oncol. 2005. 23:2686-2693.
13. Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, Baratti D, Pennacchioli E, Dileo P, Rasponi A, Ferrari A, Pilotti S, Casali PG.
    Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis
    Cancer. 2001. 92:1259-1264
14. Morel P, Duhamel A, Gobbi P.
    International prognostic scoring system for Waldenstrom macroglobulinemia
    Blood. 2009. 113:4163-4170
15. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL.
    Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
    J Clin Oncol. 2004. 22:3776-3783
16. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM.
    ABVD versus BEACOPP for Hodgkińs lymphoma when high-dose salvage is planned
    N Engl J Med. 2011. 365:203-212